Browsing Tag
imatinib mesylate
1 post
Why Wall Street and clinicians may be watching IKT-001 more closely after the Phase 3 launch
Could IKT-001 change the PAH treatment landscape? Read why Inhibikase Therapeutics’ Phase 3 launch could become a major 2026 biotech catalyst.